Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections
Eligibility Criteria
Inclusion Criteria: Not more than 20% below or 20% above ideal weight for height and estimated frame size Good health, with no clinically significant abnormal findings on the physical examination, medical history, or laboratory tests Exclusion Criteria: History of clinically significant disease History of clinically significant allergies, including drug allergy Participated in another clinical trial within the 3 months prior to study entry HIV infected Hepatitis B or C virus infected Active significant infection Prior exposure, allergy, or known hypersensitivity to PRO 140
Sites / Locations
- MDS Pharma Services
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Placebo
PRO 140 dose 1
PRO 140 dose 2
PRO 140 dose 3
PRO 140 dose 4
Intravenous placebo for PRO 140
0.1 mg/kg PRO 140 by intravenous infusion
0.5 mg/kg PRO 140 by intravenous infusion
2.0 mg/kg PRO 140 by intravenous infusion
5.0 mg/kg PRO 140 by intravenous infusion